Reporting Season: TPI Enterprises signs European codeine phosphate supply contract

Published 06-AUG-2018 12:08 P.M.


3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Name: TPI Enterprises Ltd (ASX:TPE)

Market Cap: $118 million

Last Closing Share Price: $1.38

Licenced poppy producer, TPI Enterprises Ltd (ASX:TPE) announced on Friday that it had entered into a significant multi-year supply agreement with one of Europe’s leading pharmaceutical contract manufacturing organisations.

Under the agreement TPE will ship Narcotic Raw Material from its plant in Melbourne to its Norwegian operations where it will be processed into Codeine Phosphate Active Pharmaceutical Ingredient (API).

The Codeine Phosphate API will then be delivered to one of the new customer’s several European formulation manufacturing sites for conversion into finished dosage tablets.

The agreement is for a three-year term with a minimum supply of six tonnes per annum, generating revenues of more than $9 million over the full period and $3.5 million in the 12 months to August 2019.

Few competitors in Australia

TPI is one of three licenced poppy processors in Australia, and the only one that’s Australian-owned.

It is one of only three companies globally that is vertically integrated from poppy growing through to tableting production.

TPI has developed an innovative, efficient and environmentally-sustainable extraction and purification manufacturing process which allows the company to deliver a highly competitive pricing platform.

The company’s strategy is to secure access to regulated downstream narcotics markets to leverage its reliable, cost-competitive upstream raw material capability.

Those considering this stock shouldn’t make assumptions regarding future sales, nor should they base investment decisions on performances to date. Those considering this stock should seek independent financial advice.

On track to meet or beat revenue guidance

TPI Enterprises chief executive Mr Jarrod Ritchie said: “This agreement illustrates TPI’s ability to effectively compete in this key segment of the opiates based API market, post the acquisition of the Vistin opiates business in October 2018.

“The strong customer demand we have experienced since the close of the acquisition has reinforced our belief that we are the most competitive producer of morphine and codeine based API products in the market today, and we are in the process of adding capacity at our Norway (Kragerø) facility to increase Codeine Phosphate production to meet this demand.”

Management took the opportunity to inform the market that it expected to meet or exceed revenue guidance of $20 million for the first half of 2018.

The company’s announcement prompted a 6.5 percent increase in the company’s share price on Friday.

The past performance of this product is not and should not be taken as an indication of future performance. Caution should be exercised in assessing past performance. This product, like all other financial products, is subject to market forces and unpredictable events that may adversely affect future performance.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free